PREC14A ·Filed May 19, 2026

VXRT

Vaxart, Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed4mo ago SEC0001213900-26-059144
Notable filing: PREC14A
Actionable Insight • Neutral

Monitor proxy voting results and any additional solicitation materials. If Houle gains unexpected support, it could signal shareholder unrest, but the board's slate is expected to win. No immediate trading catalyst.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d ⚠ clustered
VXRT ▼ -10.90% at T+60d
NEUTRAL call ✗ call lost -10.90% · α vs SPY -15.91% · entry $0.6100 → $0.5435
Entry anchored
May 19, 2026
via day open
T+1d
+11.48%
call +11.48% · α +11.28%
$0.6800
settled 5mo ago
T+5d
+8.20%
call +8.20% · α +6.39%
$0.6600
settled 4mo ago
T+20d
-9.67%
call -9.67% · α -10.41%
$0.5510
settled 4mo ago
T+60d
-10.90%
call -10.90% · α -15.91%
$0.5435
settled 7w ago

Price Chart

Loading chart...

Executive Summary

Vaxart filed a preliminary proxy statement for its 2026 annual meeting, facing a contested director election from stockholder Daniel P. Houle, who nominated himself and two others. The board unanimously recommends voting FOR its six nominees, citing the dissidents' lack of relevant biotech experience and small ownership stake (~0.7%). The outcome likely favors the board's slate, with limited near-term price impact.

Key Facts

  • Dissident group (Houle) owns ~0.7% of VXRT common stock
  • Board recommends voting FOR 6 nominees: Breitmeyer, Finney, Heron, Lo, Watson, Wheadon
  • Houle nominees lack biotech/pharma board experience
  • Meeting date and record date are placeholder (TBD)
  • Universal proxy card includes both slates; board urges using WHITE card

Financial Impact

Not specified

Risk Factors

  • Dissident could escalate campaign if initial vote is close
  • Continued overhang from proxy contest may distract management

Market Snapshot

Exchange
OTC
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
PREC14A Filing (Primary)0001213900-26-059144
Document: 0001213900-26-059144-index-headers.html0001213900-26-059144
Document: 0001213900-26-059144-index.html0001213900-26-059144
Document: 0001213900-26-059144.txt0001213900-26-059144
21 reports for VXRT
Performance horizon
67% Hit rate 2 of 3 directional calls best @ T+60▲ +37.66%May 1, 2026
Filters
Rows
Reports for VXRT — sortable, filterable
TypeNow
Jul 28, 2026
9w ago
8-K
NEUTRAL ★ 2/10
$0.4800 $0.5000▲ +4.17%▲ +0.79%$0.4400 (−8.33%)
Jul 7, 2026
12w ago
8-K
NEUTRAL ★ 4/10
$0.5500 $0.6000▲ +9.09%▲ +5.93%$0.4400 (−20.00%)
Jul 6, 2026
12w ago
DEFA14A
NEUTRAL ★ 5/10
$0.6200 $0.5900▼ −4.84%▼ −5.69%$0.4400 (−29.03%)
Jul 2, 2026
13w ago
DEFA14A
BULLISH ★ 5/10
$0.6400 $0.5490▼ −14.22%▼ −14.52%$0.4400 (−31.25%)
Jul 2, 2026
13w ago
8-K
NEUTRAL ★ 4/10
$0.6400 $0.5200▼ −18.75%▼ −18.34%$0.4400 (−31.25%)
Jun 26, 2026
13w ago
DEFA14A
NEUTRAL ★ 4/10
$0.5700 $0.4501▼ −21.04%▼ −20.78%$0.4400 (−22.81%)
Jun 26, 2026
13w ago
DEFA14A
NEUTRAL ★ 3/10
$0.5700 $0.4501▼ −21.04%▼ −20.78%$0.4400 (−22.81%)
Jun 26, 2026
13w ago
8-K
MIXED ★ 5/10
$0.5700 $0.4501▼ −21.04%▼ −20.78%$0.4400 (−22.81%)
Jun 16, 2026
15w ago
DEFA14A
NEUTRAL ★ 3/10
$0.5600 $0.5300▼ −5.36%▼ −6.21%$0.4400 (−21.43%)
Jun 8, 2026
16w ago
DEFA14A
NEUTRAL ★ 4/10
$0.5800 $0.5502▼ −5.14%▼ −6.53%$0.4400 (−24.14%)
Showing 10 of 21

US Market Status

Market Open — Closes in 52m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access